StemCell Therapy

Wall Street analysts expect Unity Biotechnology Inc (NASDAQ:UBX) to report ($0.54) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for Unity Biotechnologys earnings. Unity Biotechnology reported earnings of ($0.48) per share in the same quarter last year, which indicates a negative year over year growth rate of 12.5%. The business is scheduled to report its next quarterly earnings report on Wednesday, March 4th.

On average, analysts expect that Unity Biotechnology will report full-year earnings of ($1.99) per share for the current financial year, with EPS estimates ranging from ($2.05) to ($1.93). For the next financial year, analysts expect that the business will post earnings of ($2.17) per share, with EPS estimates ranging from ($2.41) to ($1.93). Zacks Investment Researchs EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Unity Biotechnology.

Unity Biotechnology (NASDAQ:UBX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of ($0.49) by ($0.05).

UBX has been the subject of a number of research analyst reports. Mizuho restated a buy rating and set a $33.00 price objective on shares of Unity Biotechnology in a report on Monday, November 18th. ValuEngine upgraded shares of Unity Biotechnology from a buy rating to a strong-buy rating in a report on Friday. Cantor Fitzgerald restated an overweight rating and set a $20.00 price objective on shares of Unity Biotechnology in a report on Thursday, December 12th. Finally, Zacks Investment Research downgraded shares of Unity Biotechnology from a buy rating to a hold rating in a report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Unity Biotechnology presently has an average rating of Buy and a consensus price target of $18.81.

Shares of UBX stock opened at $7.10 on Thursday. The firm has a 50-day moving average of $7.38 and a 200-day moving average of $7.21. Unity Biotechnology has a one year low of $5.61 and a one year high of $16.87.

A number of large investors have recently modified their holdings of the business. Bank of Montreal Can boosted its position in Unity Biotechnology by 164,400.0% during the second quarter. Bank of Montreal Can now owns 4,935 shares of the companys stock worth $47,000 after purchasing an additional 4,932 shares during the period. Aperio Group LLC bought a new position in Unity Biotechnology during the second quarter worth about $50,000. Northern Trust Corp boosted its position in Unity Biotechnology by 2.4% during the second quarter. Northern Trust Corp now owns 242,690 shares of the companys stock worth $2,306,000 after purchasing an additional 5,756 shares during the period. Bank of New York Mellon Corp boosted its position in Unity Biotechnology by 9.6% during the second quarter. Bank of New York Mellon Corp now owns 69,516 shares of the companys stock worth $660,000 after purchasing an additional 6,112 shares during the period. Finally, Tower Research Capital LLC TRC bought a new position in Unity Biotechnology during the third quarter worth about $45,000. Hedge funds and other institutional investors own 35.56% of the companys stock.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.

Recommended Story: Understanding Analyst Recommendations

Get a free copy of the Zacks research report on Unity Biotechnology (UBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

View post:
Analysts Anticipate Unity Biotechnology Inc (NASDAQ:UBX) Will Announce Earnings of -$0.54 Per Share - Riverton Roll

This entry was posted on January 12, 2020 at 2:41 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |